Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-26854165 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| JNJ-26854165 | DRUG | - |
Inclusion Criteria: * Confirmed solid malignancy, in advanced, incurable stage or not responsive to available therapies * performance status (based on the Eastern Cooperative Oncology Group assessments) of \<= 2 * life expectancy \> 3 months * must consent to skin biopsies * must meet protocol-defi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
JNJ-26854165 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed as a potential oncology therapy for patients with advanced stage or refractory solid tumors.
JNJ-26854165 is being developed by Johnson & Johnson, a multinational pharmaceutical company. The company's stock is traded under the ticker symbol JNJ on the New York Stock Exchange.
JNJ-26854165 is in Phase 1 of clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated in clinical trials to determine its safety and appropriate dosing.
JNJ-26854165 has been studied in one clinical trial, identified as NCT00676910. This was a Phase 1 study designed to determine the safety and dose of the drug in patients with advanced stage or refractory solid tumors. The trial has been completed.
JNJ-26854165 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The drug is still in clinical development and has not received approval from the U.S. Food and Drug Administration or any other regulatory agency.